CVS Caremark Replaces Amgen And Eli Lilly's Branded Drugs, Expands Biosimilar Strategy For Weak Bone Disorder - CVS Health (NYSE:CVS)

CVS Caremark Replaces Amgen And Eli Lilly's Branded Drugs, Expands Biosimilar Strategy For Weak Bone Disorder - CVS Health (NYSE:CVS)

CVS Health says new Caremark formulary changes will expand access to lower-cost osteoporosis biosimilars starting in 2026.

CVS Health expands biosimilar coverage to lower osteoporosis treatment costs

WOONSOCKET, R.I. — CVS Health announced it will expand access to more affordable osteoporosis therapies through formulary adjustments aimed at speeding up biosimilar adoption and lowering pharmacy costs for employers and members.Effective April 1, CVS Caremark will add osteoporosis biosimilars Ospomyv and Stoboclo, along with generic teriparatide options Bonsity and Tymlos, to major national commercial template formularies. These products will r…